Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05673915 · ClinicalTrials.gov registry record · NA
Study of Transcranial Direct Current Stimulation to Treat Epilepsy
A NA study of Focal Epilepsy and Generalized Onset Epilepsy, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05673915: Recruiting NA study of Focal Epilepsy and Generalized Onset Epilepsy, sponsored by Mayo Clinic.
NCT05673915 is a NA study of Focal Epilepsy and Generalized Onset Epilepsy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 168-participant average among 8 other Focal Epilepsy trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05673915, a NA study of Focal Epilepsy and Generalized Onset Epilepsy, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.
Primary Outcome
Number of seizures experienced by subjects as determined by self-reported seizure diary
Conditions Studied
Interventions
- DEVICE ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)
- DEVICE ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05673915 shows while recruiting
NCT05673915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 168-participant average among 8 other Focal Epilepsy trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Focal Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS) is the first listed.
NCT05673915 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05673915 about?
NCT05673915 is a clinical study titled "Study of Transcranial Direct Current Stimulation to Treat Epilepsy". The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.
What is the current status of trial NCT05673915?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-04-12. Estimated completion is 2026-12.
What conditions does trial NCT05673915 study?
This clinical trial studies the following conditions: Focal Epilepsy, Generalized Onset Epilepsy, Sleep-related Epileptic Encephalopathy.
What interventions are being tested in trial NCT05673915?
The interventions under investigation include: ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS) (DEVICE), ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS) (DEVICE).
Who is sponsoring clinical trial NCT05673915?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05673915 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05673915's enrollment target sits among peer trials
30 7th of 8 higher than 1 of 8 other Focal Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Focal Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Diffusion MRI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery
RECRUITING · NA
-
Breathing Rescue for SUDEP Prevention
RECRUITING · NA
-
Sleep Architecture & Cognition in Focal Epilepsy
RECRUITING · NA
-
Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables
RECRUITING · NA
-
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI